FirstHealth of the Carolinas

Clinical Trial Details

Study Title: CALGB 90601: A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients With Advanced Transitional Cell Carcinoma
Study Type: Interventional
Study Condition: Urinary Tract Cancer, Bladder Cancer
Investigator: Dr. Charles Kuzma
Phone: (910) 715-3500
Research Coordinator: Lori DeSpain
Phone: (910) 715-2200
Eligibility Criteria: Men or women, ages 18 and older, diagnosed with advanced urinary tract (renal pelvis, ureter, bladder, prostate, or urethra) cancer. For additional criteria, call the Research Coordinator or visit the study weblink.
Sponsor Organization: Cancer and Leukemia Group B
Study Rationale: Drugs used in chemotherapy, such as gemcitabine hydrochloride and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. It is not yet known whether gemcitabine hydrochloride and cisplatin are more effective when given together with or without bevacizumab in treating patients with urinary tract cancer.
Study Purpose: This randomized phase III trial is studying gemcitabine hydrochloride, cisplatin, and bevacizumab to see how well they work compared with gemcitabine hydrochloride, cisplatin, and placebo in treating patients with advanced urinary tract cancer.
Study Link: http://clinicaltrials.gov/ct2/show/NCT00942331
   
 
FirstHealth @ Facebook.comFirstHealth @ Twitter.comFirstHealth @ Pinterest.comFirstHealth @ LinkedIn.com
Physicians Employees
Working Together, First in Quality, First in Health
Site MapPrivacy PolicyTerms & ConditionsHelp © FirstHealth of the Carolinas, Inc.